285 related articles for article (PubMed ID: 11359675)
21. 5-fluorouracil permits access to a primitive subpopulation of peripheral blood stem cells.
Rice A; Barbot C; Lacombe F; Dubosc-Marchenay N; Marit G; Hau F; Boiron JM; Reiffers J
Stem Cells; 1993 Jul; 11(4):326-35. PubMed ID: 8401256
[TBL] [Abstract][Full Text] [Related]
22. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
23. Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
Triozzi PL; Tucker F; Benzies T; Balcerzak SP
Bone Marrow Transplant; 1996 Jul; 18(1):47-52. PubMed ID: 8831995
[TBL] [Abstract][Full Text] [Related]
24. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
Wong EK; Eaves C; Klingemann HG
Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
[TBL] [Abstract][Full Text] [Related]
25. Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients.
Meehan KR; Slack R; Gehan E; Herscowitz HB; Areman EM; Ebadi M; Cairo MS; Lippman ME
J Hematother Stem Cell Res; 2002 Apr; 11(2):415-21. PubMed ID: 11983113
[TBL] [Abstract][Full Text] [Related]
26. In vitro generation of cytotoxic effectors activated by interleukin 2 (IL-2): comparison of autologous peripheral blood stem cells (PBSC) from adults and children.
Valteau-Couanet D; Angevin E; Leboulaire C; Beaussier PS; Bayle C; Hartmann O; Beaujean F
Bone Marrow Transplant; 2001 Apr; 27(8):869-75. PubMed ID: 11477446
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation.
Robinson KL; Ayello J; Hughes R; van de Ven C; Issitt L; Kurtzberg J; Cairo MS
Exp Hematol; 2002 Mar; 30(3):245-51. PubMed ID: 11882362
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
[TBL] [Abstract][Full Text] [Related]
29. Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin + G-CSF in cancer patients.
Joshi SS; Miller K; Jackson JD; Warkentin P; Kessinger A
Cytotherapy; 2000; 2(1):15-24. PubMed ID: 12042051
[TBL] [Abstract][Full Text] [Related]
30. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
31. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
32. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
33. Towards endothelial-cell-directed cancer immunotherapy: in vitro expression of human recombinant cytokine genes by human and mouse primary endothelial cells.
Ojeifo JO; Su N; Ryan US; Verma UN; Mazumder A; Zwiebel JA
Cytokines Mol Ther; 1996 Jun; 2(2):89-101. PubMed ID: 9384693
[TBL] [Abstract][Full Text] [Related]
34. Biological characterization of CD34+ cells mobilized into peripheral blood.
Lemoli RM; Tafuri A; Fortuna A; Catani L; Rondelli D; Ratta M; Tura S
Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S47-50. PubMed ID: 9989890
[TBL] [Abstract][Full Text] [Related]
35. Secondary cytokine production by lymphoid cells used in cellular immunotherapy.
Schoof DD; Hunt P; Obando JA; Cusack JC; Andrews V; Terashima Y; Eberlein TJ
Surg Oncol; 1992 Apr; 1(2):163-72. PubMed ID: 1341247
[TBL] [Abstract][Full Text] [Related]
36. Experimental evidence of interleukin-2 activity in bone marrow transplantation.
Mazumder A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S37-42. PubMed ID: 9457392
[TBL] [Abstract][Full Text] [Related]
37. Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer.
Miller JS; Tessmer-Tuck J; Blake N; Lund J; Scott A; Blazar BR; Orchard PJ
Exp Hematol; 1997 Oct; 25(11):1140-8. PubMed ID: 9328450
[TBL] [Abstract][Full Text] [Related]
38. Synergistic effects of IL-7 and IL-12 on human T cell activation.
Mehrotra PT; Grant AJ; Siegel JP
J Immunol; 1995 May; 154(10):5093-102. PubMed ID: 7730615
[TBL] [Abstract][Full Text] [Related]
39. Effects of recombinant cytokines on colony formation by irradiated human cord blood CD34+ hematopoietic progenitor cells.
Goff JP; Shields DS; Boggs SS; Greenberger JS
Radiat Res; 1997 Jan; 147(1):61-9. PubMed ID: 8989371
[TBL] [Abstract][Full Text] [Related]
40. Expression of interleukin-10 in isolated CD8+ T cells and monocytes from growth factor-mobilized peripheral blood stem cell products: a mechanism of immune dysfunction.
Varney ML; Ino K; Ageitos AG; Heimann DG; Talmadge JE; Singh RK
J Interferon Cytokine Res; 1999 Apr; 19(4):351-60. PubMed ID: 10334386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
